Tools & Downloads

Download patient education and reference materials to your desktop. Links for healthcare professionals also are available.

Dosing Schedules:
	For patients NOT TAKING carbamazepine, phenytoin, phenobarbital, primidone, rifampin, or valproate (PDF, 344K) For LAMICTAL For LAMICTAL ODT For patients TAKING valproate (PDF, 343K) For LAMICTAL For LAMICTAL ODT For patients TAKING carbamazepine, phenytoin, phenobarbital, primidone, or rifampin and NOT TAKING valproate (PDF, 344K) For LAMICTAL For LAMICTAL ODT

Medication Guide (PDF, 136K) Patient Booklet (PDF, 4843K) Patient Mood Chart (PDF, 224K)

Important Safety Information

LAMICTAL ODT is another form of LAMICTAL.
Cases of life-threatening serious rashes, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and/or rash-related death, have been caused by LAMICTAL. The rate of serious rash is greater in pediatric patients than in adults. Additional factors that may increase the risk of rash include:
- coadministration with valproate
- exceeding recommended initial dose of LAMICTAL
- exceeding recommended dose escalation of LAMICTAL
Benign rashes are also caused by LAMICTAL; however, it is not possible to predict which rashes will prove to be serious or life-threatening. LAMICTAL should be discontinued at the first sign of rash, unless the rash is clearly not drug-related.
Hypersensitivity reaction may be fatal or life-threatening. Early signs of hypersensitivity (eg, fever, lymphadenopathy) may present without rash; if signs present, patient should be evaluated immediately. LAMICTAL should be discontinued if alternate etiology for hypersensitivity signs is not found.
Prior to initiation of treatment with LAMICTAL, the patient should be instructed that a rash or other signs or symptoms of hypersensitivity (eg, fever, lymphadenopathy) may herald a serious medical event and that the patient should report any such occurrence to a physician immediately.
Acute multiorgan failure has resulted (some cases fatal).
Blood dyscrasias (eg, neutropenia, thrombocytopenia, pancytopenia) may result either with or without an associated hypersensitivity syndrome.
Antiepileptic drugs, including LAMICTAL ODT, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.
Patients treated with any antiepileptic drug for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
Patients, their caregivers, and families should be informed that antiepileptic drugs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

LAMICTAL and LAMICTAL ODT are indicated for the maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (≥18 years of age) treated for acute mood episodes with standard therapy. The effectiveness of LAMICTAL and LAMICTAL ODT in the acute treatment of mood episodes has not been established.

Medication Guide for LAMICTAL^® (lamotrigine) and LAMICTAL^® ODT^™ (lamotrigine) Orally Disintegrating Tablets

Complete Prescribing Information for LAMICTAL^® (lamotrigine) and LAMICTAL^® ODT^™ (lamotrigine) Orally Disintegrating Tablets

Complete Prescribing Information is provided in Adobe's Portable Document Format (PDF). To view these documents, you will need Adobe Acrobat Reader. If you do not have it and you are unable to or do not wish to download Acrobat Reader, but still wish to receive complete Prescribing Information, please click here .

This website is funded and developed by GlaxoSmithKline.
This site is intended for US healthcare professionals only.
© 1997-2010 GlaxoSmithKline. All Rights Reserved.
Legal Notices | Privacy Statement | Medicine Savings | Contact Us